share_log

Cassava Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Remi Barbier(5.7%)

SEC announcement ·  Feb 1 16:03
Summary by Moomoo AI
Cassava Sciences, Inc., a biotechnology company, has filed an amended Schedule 13G/A with the U.S. Securities and Exchange Commission (SEC) on February 1, 2024. The filing indicates that Remi Barbier, President, CEO, and Chairman of Cassava Sciences, beneficially owns 2,488,531 shares of the company's common stock, representing 5.7% of the class. The document details that Barbier has sole voting and dispositive power over 1,778,465 shares and shared voting and dispositive power over 710,066 shares. The filing, dated December 31, 2023, is a routine disclosure that specifies the ownership percentage and voting rights of significant shareholders. It also includes a certification by Barbier, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Cassava Sciences, Inc., a biotechnology company, has filed an amended Schedule 13G/A with the U.S. Securities and Exchange Commission (SEC) on February 1, 2024. The filing indicates that Remi Barbier, President, CEO, and Chairman of Cassava Sciences, beneficially owns 2,488,531 shares of the company's common stock, representing 5.7% of the class. The document details that Barbier has sole voting and dispositive power over 1,778,465 shares and shared voting and dispositive power over 710,066 shares. The filing, dated December 31, 2023, is a routine disclosure that specifies the ownership percentage and voting rights of significant shareholders. It also includes a certification by Barbier, stating that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more